About Enhancer

Enhancer ID: E_02_0867
Species: human
Position : chr1:13041306-13127367
Biosample name:
Experiment class : Low throughput
Enhancer type: Super-Enhancer
Disease: --
Pubmed ID:  25801169
Enhancer experiment: Luciferase Reporter Assay
Enhancer experiment description: The five super-enhancers show physical interactions with their respective associated genes and are located within insulated neighborhoods in the ESC genome , suggesting that these genes represent the bona fide physiological targets of the five SEs.

About Target gene

Target gene : Prdm14(Prdm14),Prdm14(Prdm14),Prdm14(Prdm14),Prdm14(Prdm14),Prdm14(Prdm14),Prdm14(Prdm14),Prdm14(Prdm14),Prdm14(Prdm14),Prdm14(Prdm14),Prdm14(Prdm14),Prdm14(Prdm14),Prdm14(Prdm14)
Strong evidence: CRISPR/Cas9
Less strong evidence: --
Target gene experiment description: The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene;The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene;The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene;The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene;The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene;The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene;The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene;The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene;The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene;The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene;The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene;The results showed that deletion of most (12/14) super-enhancer constituents led to reduced expression of the associated gene, while in one case (Prdm14 E5) the deletion caused a small increase in expression of the associated gene

About TF

TF name : Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)Oct4Sox2(ANOP3,MCOPS3)Nanog(NANOG)
TF experiment: ChIP-seq
TF experiment description: ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.;ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.;ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.;ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.;ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.;ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.;ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.;ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.;ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.;ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.;ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.;ChIP-Seq binding profiles for OCT4,SOX2 and NANOG (merged) and Mediator (MED1) at the miR-290-295 locus in ES cells.Enhancer activity measured in luciferase reporter assays in wild type cells and the change in enhancer activity after OCT4 shutdown is plotted for each constituent enhancer within the super-enhancer. The super-enhancer is depicted as a black bar above the binding profiles. The difference in values after OCT4 shutdown is statistically significant for all constituents, except from miR-290-295 M1, M3 and M5.

About Function

Enhancer function : --
Enhancer function experiment: --
Enhancer function
experiment description:		 --

About SNP

SNP ID: --

Upstream Pathway Annotation of TF

GeneName Pathway Name Source Gene Number
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Deactivation of the beta-catenin transactivating complex reactome 42
Sox2 POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Sox2 POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Sox2 Transcriptional regulation of pluripotent stem cells reactome 28
Sox2 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
Sox2 Hs_Dopaminergic_Neurogenesis_WP2855_87239 wikipathways 19
Sox2 Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 wikipathways 12
Sox2 Hs_Mesodermal_Commitment_Pathway_WP2857_87780 wikipathways 47
Sox2 Hs_Ectoderm_Differentiation_WP2858_89329 wikipathways 56
Nanog POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation reactome 13
Nanog POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation reactome 10
Nanog Transcriptional regulation of pluripotent stem cells reactome 28

Enhancer associated network

The number on yellow line represents the distance between enhancer and target gene

Expression of target genes for the enhancer

Enhancer associated SNPs